U.K. regenerative medicine specialist, Tissue Regenix plans to expand its decellularization (dCELL®) Technology into other medical sectors.
Tissue Regenix’s patented dCELL® Technology is a multi-tissue regenerative medical platform which can be used in a wide range of medical applications to allow the body to regenerate critical tissue through utilizing decellularized animal and human biological materials. DNA and other cellular material are removed from the tissue, leaving the acellular scaffold intact. dCELL® Technology provides support for cell migration during the healing process all while preserving necessary tissue strength. It avoids rejection by the patient’s body and integrates into the host tissue without the use of harsh chemicals or treatments.
Having established its technology with chronic and acute wound care product, DermaPure®, Tissue Regenix plans to progress into other applications in early 2018. The company has opened up new possibilities in regenerative medicine in the U.K., applying its dCELL® Technology to several therapeutic applications including orthopaedics and sports medicine. It is currently undertaking clinical trials in the EU and will look to introduce dCELL® Technology to orthopedic applications, initially addressing ACL repair.
Tissue Regenix will be attending the American Academy of Orthopedic Surgeons (AAOS) annual meeting in March to share more information on its progress with a team of luminary orthopedic and sports medicine experts. The company will be exhibiting at the American Academy of Orthopedic Surgeons meeting in San Diego, CA March 14-17.
“We have seen first-hand how life changing these products have been in Europe, and we are thrilled to bring our dCELL® Technology to the United States to help a new population of patients heal faster and more effectively,” said Antony Odell, CEO of Tissue Regenix. “These solutions are bringing hope to people who have conditions that may otherwise be beyond repair.”
“The application of dCELL® Technology in orthopedics will give surgeons and clinicians an innovative new way to provide care to patients requiring anterior cruciate ligament (ACL) reconstruction, meniscus replacement and other injuries,” said Drew Distin, VP of Orthopedics at Tissue Regenix.
Source: Business Wire